The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T).
Jonathan S. Cebon
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Keith Flaherty
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Jeffrey S. Weber
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Kevin Kim
Research Funding - GlaxoSmithKline
Jeffrey R. Infante
Consultant or Advisory Role - GlaxoSmithKline (U)
Adil Daud
No relevant relationships to disclose
Omid Hamid
Research Funding - GlaxoSmithKline
Richard Kefford
Consultant or Advisory Role - GlaxoSmithKline
Lynn Mara Schuchter
Research Funding - GlaxoSmithKline
Jeffrey Alan Sosman
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Bristol-Myers Squibb
Mario Sznol
Consultant or Advisory Role - BeiGene; Bristol-Myers Squibb; Nektar
William Howard Sharfman
Consultant or Advisory Role - Merck
Rene Gonzalez
Consultant or Advisory Role - GlaxoSmithKline; Roche
Honoraria - Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Miles Cameron Andrews
No relevant relationships to disclose
Roxana Stefania Dronca
No relevant relationships to disclose
Georgina Long
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Roche
Honoraria - Roche
Shonda M Little
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Peng Sun
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Kiran Patel
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Robert R. McWilliams
No relevant relationships to disclose